Patents by Inventor Venkata S. Neti

Venkata S. Neti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10295543
    Abstract: Therapeutic compositions for treating diseased cells such as cancer cells in a patient, formulated from a plurality of therapeutic agents selected from radiopharmaceuticals, chemotherapeutic agents and radionuclide labeled antibodies. Methods for predicting the response of an individual patient's cells to therapeutic intervention are also disclosed.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: May 21, 2019
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Roger W. Howell, John M. Akudugu, Jordan B. Pasternack, Venkata S. Neti
  • Patent number: 9804167
    Abstract: Disclosed is a method for predicting the optimal amounts of radiopharmaceutical and/or chemotherapy agents to administer to a patient, by determining the level of saturation of the therapeutic agents in the patient's cells. The method comprises measuring cellular incorporation of the candidate therapeutic agents in a target cell population on a cell-by-cell basis. The method is able to identify an optimal cocktail of therapeutic agents for treatment of a disease. A method of high-throughput drug discovery incorporating this method, and a 2-stage targeting method of treating a disease using this method are also disclosed.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: October 31, 2017
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: John M. Akudugu, Venkata S. Neti, Roger W. Howell
  • Patent number: 9623262
    Abstract: A system, method and computer program product to determine radiation dose from radionuclides used to treat a patient in need thereof. The present invention allows users to visualize and understand the impact of radionuclide choice, distribution of activity in the cell, distribution of activity among the cells, cell dimensions, cell separation distance, cluster size, and radiobiological response parameters on the capacity to kill populations of cells. All of these parameters can play a substantial role in determining the surviving fraction of cells. Accordingly, this system, method and computer program product can assist in designing treatment plans for therapeutic radiopharmaceuticals suited to individual needs.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 18, 2017
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Behrooz Vaziri, Han Wu, Roger W. Howell, John M. Akudugu, Venkata S. Neti
  • Publication number: 20150265730
    Abstract: Disclosed is a method for predicting the optimal amounts of radiopharmaceutical and/or chemotherapy agents to administer to a patient, by determining the level of saturation of the therapeutic agents in the patient's cells. The method comprises measuring cellular incorporation of the candidate therapeutic agents in a target cell population on a cell-by-cell basis. The method is able to identify an optimal cocktail of therapeutic agents for treatment of a disease. A method of high-throughput drug discovery incorporating this method, and a 2-stage targeting method of treating a disease using this method are also disclosed.
    Type: Application
    Filed: October 28, 2014
    Publication date: September 24, 2015
    Inventors: John M. Akudugu, Venkata S. Neti, Roger W. Howell